SOUTH SAN FRANCISCO, Calif. — October 6, 2022 — Epicrispr Biotechnologies, a biotechnology company developing therapies to modulate gene expression using the compact, non-cutting dCas protein, today announced that the company will be participating in the Solebury / BMO Fall Private Company Showcase, taking place Thursday, October 13, 2022, in New York. The event is co-hosted by BMO Capital Markets and Goodwin Law.
Chief Executive Officer, Amber Salzman, Ph.D., is scheduled to present on October 13 at 2:40 pm ET. The Company will be taking meetings with select investors and analysts.
Interested parties can register for the event on the Solebury website, found here.
About Epicrispr Biotechnologies
Epicrispr Biotechnologies is a leading epigenetic engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through its exclusive license of CasMINI, the most compact Cas DNA-binding protein to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epicrispr Biotechnologies has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypercholesterolemia (HeFH), as well as other programs. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic.bio.com for more information or follow us on Twitter and LinkedIn.
Investor Contact
Jessica Vo
Gilmartin Group, LLC
jessi@gilmartinir.com
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com